Insulin resistance, defined as an impaired ability of insulin to modulate glucose metabolism in target tissues, is a major therapeutic target in type 2 diabetes. Accurate measurement of insulin action is necessary for the development of novel insulin-sensitizing drugs. The hyperinsulinemic euglycemic clamp, which has been used primarily to assess insulin-mediated glucose disposal, is widely regarded as the reference method. Profil Institute offers unrivaled expertise in the measurement of insulin sensitivity using its automated two-step hyperinsulinemic euglycemic clamp technology. This approach offers greater accuracy and less variability than manual clamps that are more operator dependent.
